澳大利亚新实施儿童通用流感规划的影响:2018年住院儿童的疫苗覆盖率、疫苗有效性与疾病流行病学
2018年澳大利亚各辖区为学龄前儿童建立免费四价流感疫苗(QIV)规划,并继续由国家免疫规划(NIP)为土著儿童和有合并症的儿童提供QIV。研究通过12家PAEDS-FluCAN哨点医院前瞻性招募≤16岁因急性呼吸道疾病住院且实验室确诊流感的儿童,评估政策变化对疾病负担和疫苗覆盖率的影响,并报告疫苗有效性(VE)。结果显示458例流感住院儿童中,QIV预防流感住院的VE为78.8%(95%CI:66.9;86.4);与2017年(n=1268例)相比,澳大利亚儿童重症流感显著减少。
要点
- 2018年458例流感住院儿童中,12.0%接种疫苗,而流感检测阴性对照组为36.0%。
- QIV预防儿童流感住院的疫苗有效性为78.8%(95%CI:66.9;86.4)。
- 与2017年(n=1268例)相比,澳大利亚儿童重症流感显著减少。
核心结论
- 与2017年(n=1268例)相比,澳大利亚儿童重症流感显著减少,可能得益于疫苗覆盖率提高和高疫苗有效性。
- 尽管推出了辖区资助的学龄前儿童规划及NIP资助的高危儿童疫苗,仍需提高覆盖率以確保障儿童流感发病和死亡得到充分保护。
研究设计与样本
- 前瞻性研究,从12家PAEDS-FluCAN哨点医院(2018年4月至10月)招募≤16岁因急性呼吸道疾病住院的儿童。
- 实验室确诊流感的住院儿童为病例,流感检测阴性的急性呼吸道疾病住院儿童为对照。
- 疫苗有效性(VE)通过病例和对照中接种疫苗的调整比值比计算。
主要发现
- 共458名儿童因流感住院:31.7%年龄<2岁,5.0%为土著,40.6%有易致重症流感的医学合并症。
- 90.6%的儿童检出甲型流感(A/H1N1:38.0%;A/H3N2:3.1%;A/未分型48.6%)。
- 中位住院时间为2天(IQR:1,3),8.1%入住ICU,奥司他韦使用不频繁(16.6%)。
- 发生2例院内死亡(0.45%)。
- 12.0%的流感病例接种了疫苗,而流感检测阴性对照中为36.0%。
关键数值与推荐
- QIV预防流感住院的疫苗有效性估计为78.8%(95%CI:66.9;86.4)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: New jurisdictionally-based vaccination programs were established providing free quadrivalent influenza vaccine (QIV) for preschool Australian children in 2018. This was in addition to the National Immunisation Program (NIP) funded QIV for Indigenous children and children with comorbid medical conditions. We assessed the impact of this policy change on influenza disease burden and vaccine coverage, as well as report on 2018 vaccine effectiveness in a hospital-based surveillance system. METHODS: Subjects were recruited prospectively from twelve PAEDS-FluCAN sentinel hospital sites (April until October 2018). Children aged ≤16 years hospitalised with an acute respiratory illness (ARI) and laboratory-confirmed influenza were considered cases. Hospitalised children with ARI who tested negative for influenza were considered controls. VE estimates were calculated from the adjusted odds ratio of vaccination in cases and controls. RESULTS: A total of 458 children were hospitalised with influenza: 31.7% were <2 years, 5.0% were Indigenous, and 40.6% had medical comorbidities predisposing to severe influenza. Influenza A was detected in 90.6% of children (A/H1N1: 38.0%; A/H3N2: 3.1%; A/unsubtyped 48.6%). The median length of stay was 2 days (IQR: 1,3) and 8.1% were admitted to ICU. Oseltamivir use was infrequent (16.6%). Two in-hospital deaths occurred (0.45%). 12.0% of influenza cases were vaccinated compared with 36.0% of test-negative controls. Vaccine effectiveness of QIV for preventing influenza hospitalisation was estimated at 78.8% (95%CI: 66.9; 86.4). CONCLUSIONS: Compared with 2017 (n = 1268 cases), a significant reduction in severe influenza was observed in Australian children, possibly contributed to by improved vaccine coverage and high vaccine effectiveness. Despite introduction of jurisdictionally-funded preschool programs and NIP-funded vaccine for children with risk factors for severe disease, improved coverage is required to ensure adequate protection against paediatric influenza morbidity and mortality.
引用
- Blyth CC, Cheng AC, Crawford NW, et al. The impact of new universal child influenza programs in Australia: Vaccine coverage, effectiveness and disease epidemiology in hospitalised children in 2018. Vaccine. 2020. PMID: 32107062. doi:10.1016/j.vaccine.2020.02.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。